A future goal can be the evaluation of preclinical data on novel tracers, with a special focus on binding properties that may differ in different kinds of Tau deposits, with a potential crucial impact on differential diagnosis in the dementia field and tauopathies. This evidence concerns the gene MAPT and dementia.